Abstract
Matrix coils have been developed to prevent aneurysm recanalization. Midterm anatomic results in a prospective multicenter consecutive series including patients treated with GDC or Matrix coils for ruptured aneurysms are presented. Five hundred seventeen patients harboring ruptured aneurysms were treated with GDC (276 patients) or Matrix coils (241 patients). Postoperative and midterm anatomic results were evaluated anonymously and independently using the Modified Montreal Scale (complete occlusion, neck remnant, and aneurysm remnant). In the midterm follow-up (mean, 16.7 months in the GDC group and 15.4 months in the Matrix group), complete occlusion was reported in 95/276 aneurysms (34.4%) in the GDC group and 80/241 (33.2%) in the Matrix group, neck remnant in 127/276 (46.0%) in the GDC group and 118/241 (49.0%) in the Matrix group, and aneurysm remnant in 54/276 (19.6%) in the GDC group and 43/241 (17.8%) in the Matrix group. Evolution of aneurysm occlusion was improvement in 35/272 aneurysms (12.9%) in the GDC group and 27/239 (11.3%) in the Matrix group, stable situation in 98/272 (36.0%) in the GDC group and 97/239 (40.6%) in the Matrix group, and worsening in 139/272 (51.1%) in the GDC group and 115/239 (48.1%) in the Matrix group. A total of 32/517 patients were retreated during the follow-up period: 9/276 (3.3%) in the GDC group and 23/241 (9.5%) in the Matrix group (P = .003). In this study, midterm anatomic results and evolution of aneurysm occlusion were not different in patients with ruptured aneurysms treated with GDC or Matrix coils.
Highlights
MethodsFive hundred seventeen patients harboring ruptured aneurysms were treated with GDC (276 patients) or Matrix coils (241 patients)
AND PURPOSE: Matrix coils have been developed to prevent aneurysm recanalization
In this study, midterm anatomic results and evolution of aneurysm occlusion were not different in patients with ruptured aneurysms treated with GDC or Matrix coils
Summary
Five hundred seventeen patients harboring ruptured aneurysms were treated with GDC (276 patients) or Matrix coils (241 patients). The initial CLARITY series (conducted between November 3, 2006, and June 29, 2007) involved patients treated with GDCs (CLARITY-GDC). In the second CLARITY series (conducted between April 23, 2007, and September 5, 2008), patients were treated with Matrix detachable coils (CLARITY-Matrix). In both series,[1,2] patients were consecutively included. All patients were treated with GDCs. During the second period, all patients were treated with Matrix detachable coils. The second series (CLARITY-Matrix) was started after the end of the inclusions in the first series (CLARITY-GDC). The technique of treatment was selected only by the time during which the treatment was performed, and no blinding was done
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
